
Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.
Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.
This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.
Published: May 3rd 2016 | Updated:
Published: February 12th 2020 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.